PMID: 9169305Apr 1, 1997Paper

Is there a role for a pure noradrenergic drug in the treatment of depression?

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
S Montgomery

Abstract

Depression is thought to result from a dysfunction in the noradrenergic or serotonergic systems. The noradrenergic system appears to be associated with increased drive, whereas the serotonergic system relates more to changes in mood and it is possible that the different symptoms of depression may benefit from drugs acting mainly on one or other of the neurotransmitter systems. A series of studies has shown that interruption of serotonin synthesis compromises the efficacy of serotonin but not noradrenaline reuptake inhibitors, and interruption of noradrenaline synthesis compromises the efficacy of noradrenaline but not serotonin reuptake inhibitors (SSRIs). This suggests that the two classes of drugs owe their activity to functional changes in different neurotransmitter systems. Reboxetine represents a new class of drugs-the selective noradrenaline reuptake inhibitors (NARIs). It acts specifically at noradrenergic sites unlike the non-selective tricyclic antidepressants (TCAs). NARIs have a role in the treatment of depression, either alone or as adjunctive therapy.

References

Jan 1, 1979·Neuropsychobiology·I ModaiH Wijsenbeek
Oct 1, 1991·BMJ : British Medical Journal·C M BeasleyD N Masica
Sep 13, 1988·European Journal of Pharmacology·B M BaronM W Dudley
Sep 1, 1986·Acta Psychiatrica Scandinavica·I J SharmaB R Agnihotri
Mar 1, 1972·Archives of General Psychiatry·J W MaasH Dekirmenjian
Aug 1, 1968·Archives of General Psychiatry·J W MaasH Dekirmenjian
Oct 1, 1984·The American Journal of Psychiatry·J W MaasJ M Davis
Jan 1, 1981·Acta Psychiatrica Scandinavica. Supplementum·A Aberg
Jan 1, 1984·Psychopharmacology Bulletin·S PuzyńskiM Załuska
Mar 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S A MontgomeryG C Dunbar
Jan 1, 1993·International Clinical Psychopharmacology·S A Montgomery, G Dunbar
Mar 1, 1993·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M H TeicherJ O Cole
Apr 1, 1997·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·B E Leonard

❮ Previous
Next ❯

Citations

Apr 21, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·H CorrêaJ P Macher
Mar 25, 2004·British Journal of Sports Medicine·M F PiacentiniK De Meirleir
Dec 27, 2011·Behavioural Brain Research·Linlin ZhenJianchun Pan
Jul 1, 2005·European Journal of Pharmacology·Ying XuXue-Jun Li
Jan 1, 1998·International Journal of Psychiatry in Clinical Practice·D BaldwinM Lagnado
Oct 31, 2002·Human Psychopharmacology·I. Hindmarch
Apr 25, 2006·Journal of Clinical Psychopharmacology·Arash MowlaAzadeh Pani
Jun 28, 2008·The American Journal of Drug and Alcohol Abuse·Arash MowlaAbdul Hamid Chohedri
Jul 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Dennis K MillerLinda P Dwoskin
Aug 13, 2002·Journal of Clinical Psychopharmacology·Vittorino AndreoliMarcio Versiani
Jan 25, 2003·Journal of Clinical Psychopharmacology·Stuart MontgomeryGerri E Schwartz
Mar 27, 2003·Therapeutic Drug Monitoring·Daniel OhmanFinn Bengtsson
Sep 14, 2000·International Journal of Geriatric Psychiatry·E Aguglia
Dec 1, 2000·The Annals of Pharmacotherapy·A C Scates, P M Doraiswamy
Jul 20, 2002·Medicine and Science in Sports and Exercise·Maria Francesca PiacentiniKenny De Meirleir

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
H BerzewskiC A Gagiano
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
A DubiniV Polin
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
B Leonard
© 2021 Meta ULC. All rights reserved